Terms: = Lymphoma AND BCL3, P20749, 602, ENSG00000069399, D19S37, BCL4 AND Treatment
77 results:
1. Multifaceted roles for bcl3 in cancer: a proto-oncogene comes of age.
Seaton G; Smith H; Brancale A; Westwell AD; Clarkson R
Mol Cancer; 2024 Jan; 23(1):7. PubMed ID: 38195591
[TBL] [Abstract] [Full Text] [Related]
2. Bcl-3 regulates T cell function through energy metabolism.
Liu H; Zeng L; Pan M; Huang L; Li H; Liu M; Niu X; Zhang C; Wang H
BMC Immunol; 2023 Oct; 24(1):35. PubMed ID: 37794349
[TBL] [Abstract] [Full Text] [Related]
3. BCL-3 Promotes Intracerebral Hemorrhage Progression by Increasing Blood-Brain Barrier Permeability, Inflammation, and Cell Apoptosis via Endoplasmic Reticulum Stress.
Yin H; Ran Z; Luo T; Jin Z; Ma J
Mediators Inflamm; 2023; 2023():1420367. PubMed ID: 37736616
[TBL] [Abstract] [Full Text] [Related]
4. [Regulation of Baicalin on Growth of Extranodal NK/T Cell lymphoma Cells through FOXO3/
Duan XH; Li H; Lyu Y; Liu J; Wang SX; Wu ZT; Wang BX; Lu M; Wang JH; Liang R
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):730-738. PubMed ID: 37356933
[TBL] [Abstract] [Full Text] [Related]
5. Cardiovascular Toxicities Associated with Anaplastic lymphoma Kinase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase).
Niimura T; Miyata K; Hamano H; Nounin Y; Unten H; Yoshino M; Mitsuboshi S; Aizawa F; Yagi K; Koyama T; Goda M; Kanda Y; Izawa-Ishizawa Y; Zamami Y; Ishizawa K
Drug Saf; 2023 Jun; 46(6):545-552. PubMed ID: 37106270
[TBL] [Abstract] [Full Text] [Related]
6. Nomograms for predicting overall survival and cancer-specific survival in patients with head and neck non-Hodgkin lymphoma: A population-based study.
Peng J; Chen J; Liu Y; Lyu J; Zhang B
Medicine (Baltimore); 2023 Feb; 102(6):e32865. PubMed ID: 36820559
[TBL] [Abstract] [Full Text] [Related]
7. Meta-Analysis of Survival Effects of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1).
Jeong SY; Lee KJ; Cha J; Park SY; Kim HS; Kim JH; Lee JJ; Kim N; Park ST
Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557069
[TBL] [Abstract] [Full Text] [Related]
8. Use of ALK-tyrosine kinase inhibitors (ALK TKI) in clinical practice, overall survival, and treatment duration - a Swedish nationwide retrospective study.
Lauppe R; Nilsson FOL; Fues Wahl H; Lilja M; Vikström A; T Asanin S
Acta Oncol; 2022 Nov; 61(11):1354-1361. PubMed ID: 36368902
[TBL] [Abstract] [Full Text] [Related]
9. Predictors of Secondary Lung Cancer Among Hodgkin lymphoma Survivors: A Nationwide Analysis.
Alnimer Y; Ali MKM
Clin Lung Cancer; 2022 Dec; 23(8):e510-e518. PubMed ID: 36008241
[TBL] [Abstract] [Full Text] [Related]
10. Molecular characterization, expression and anti-tumor function analysis of yak IFITM2 gene.
Wang H; Wang L; Luo X; Guan J; Zhang X; Zhang L; Xiang Y
Int J Biol Macromol; 2022 Jun; 209(Pt A):405-412. PubMed ID: 35381283
[TBL] [Abstract] [Full Text] [Related]
11. Bcl-3: A Double-Edged Sword in Immune Cells and Inflammation.
Liu H; Zeng L; Yang Y; Guo C; Wang H
Front Immunol; 2022; 13():847699. PubMed ID: 35355979
[TBL] [Abstract] [Full Text] [Related]
12. Cost-effectiveness and value of information analyses of Bruton's tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States.
Alrawashdh N; McBride A; Slack M; Persky D; Andritsos L; Abraham I
J Manag Care Spec Pharm; 2022 Apr; 28(4):390-400. PubMed ID: 35332792
[No Abstract] [Full Text] [Related]
13. bcl3 expression is strongly associated with the occurrence of breast cancer relapse under tamoxifen treatment in a retrospective cohort study.
Czapiewski P; Cornelius M; Hartig R; Kalinski T; Haybaeck J; Dittmer A; Dittmer J; Ignatov A; Nass N
Virchows Arch; 2022 Mar; 480(3):529-541. PubMed ID: 35020071
[TBL] [Abstract] [Full Text] [Related]
14. Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies.
Zhang T; Sun J; Li J; Zhao Y; Zhang T; Yang R; Ma X
BMC Cancer; 2021 May; 21(1):618. PubMed ID: 34039310
[TBL] [Abstract] [Full Text] [Related]
15. CDK1 is up-regulated by temozolomide in an NF-κB dependent manner in glioblastoma.
Voce DJ; Bernal GM; Cahill KE; Wu L; Mansour N; Crawley CD; Campbell PS; Arina A; Weichselbaum RR; Yamini B
Sci Rep; 2021 Mar; 11(1):5665. PubMed ID: 33707466
[TBL] [Abstract] [Full Text] [Related]
16. The Discovery of a Novel Antimetastatic bcl3 Inhibitor.
Soukupová J; Bordoni C; Turnham DJ; Yang WW; Seaton G; Gruca A; French R; Lee KY; Varnava A; Piggott L; Clarkson RWE; Westwell AD; Brancale A
Mol Cancer Ther; 2021 May; 20(5):775-786. PubMed ID: 33649105
[TBL] [Abstract] [Full Text] [Related]
17. Lenalidomide with Rituximab for Previously Treated Follicular lymphoma and Marginal Zone lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Witlox WJA; Grimm SE; Riemsma R; Armstrong N; Ryder S; Duffy S; Carrera VH; Posadzki P; Worthy G; Pouwels XGLV; Ramaekers BLT; Kleijnen J; Joore MA; van Asselt ADI
Pharmacoeconomics; 2021 Feb; 39(2):171-180. PubMed ID: 33145711
[TBL] [Abstract] [Full Text] [Related]
18. Pneumocystis jirovecii pneumonia in diffuse large B-cell lymphoma treated with R-CHOP.
Lee JY; Kang M; Suh KJ; Kim JW; Kim SH; Kim JW; Kim YJ; Song KH; Kim ES; Kim HB; Lee KW; Kim JH; Bang SM; Lee JS; Lee JO
Mycoses; 2021 Jan; 64(1):60-65. PubMed ID: 32970331
[TBL] [Abstract] [Full Text] [Related]
19. The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphoma.
Habbous S; Guo H; Beca J; Dai WF; Isaranuwatchai W; Cheung M; Chan KKW
Cancer Med; 2020 Oct; 9(19):7072-7082. PubMed ID: 32794362
[TBL] [Abstract] [Full Text] [Related]
20. treatment outcomes in children with Acute lymphoblastic leukemia with versus without coexisting Down's syndrome: A systematic review and meta-analysis.
Liao W; Liu Y
Medicine (Baltimore); 2020 Jul; 99(29):e21015. PubMed ID: 32702842
[TBL] [Abstract] [Full Text] [Related]
[Next]
